Please assess the completion status of the following clinical trial:

Trial Title: IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Must meet 1987 Revised Criteria for the Classification of Rheumatoid Arthritis defined as the diagnosis of the referring physician.~2. Persistent knee swelling (\>ARA grade 2) for 2 weeks, and no recent intra-articular corticosteroid injection.~3. Age 18 years and older.~4. Must be on Disease modifying anti rheumatic drugs (DMARDs) such as methotrexate, plaquenil and/or prednisone.~Exclusion Criteria:~1. Patients having received intra-articular corticosteroid joint injection within the last 2-4 weeks.~2. Patients with active systemic or joint infections.~3. Women who are pregnant (pregnancy status will be self-reported)~4. Patients under 18 years of age~5. Non-English speakers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DMARD's Responder and Non-Responder (Type: OTHER): In the first group of subjects, blood samples will be obtained from (50) RA subjects with Disease modifying anti rheumatic drugs (DMARDs) such as methotrexate, plaquenil and/or prednisone that achieve remission (DAS28\<2.6). The subjects that achieve remission (DAS28\<2.6), blood will only be taken once at the subjects routine visit. Subject's that are non-responder to DMARDS will go onto group 2.
- DMARD's plus Cimzia (Certolizumab pegol) (Type: OTHER): The second group will consist of (150) RA subjects that did not respond to DMARDs. These patients will further receive (DMARDs) such as methotrexate, plaquenil and/or prednisone as well as Cimzia®. In this Arm, blood samples will be collected onset of the study as well as 3 and 6 months after treatment with Cimzia at subject's visit through our collaboration with the aforementioned rheumatologists.

Based on this trial design, predict the completion outcome and termination type (if applicable).